Bifemelane (hydrochloride)

62232-46-6

305.84

10 mM in DMSO

Neuronal Signaling

Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 uM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 uM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.
In Vitro: Bifemelane inhibits MAO-A in a dose-dependent manner, with Kis of 4.2+/-0.2 and 14.1+/-0.7 uM in human brain synaptosomes and human liver mitochondria respectively.

Bifemelane inhibits MAO-B activities in a dose-dependent manner, with Kis of 46.0+/-3.6 and 65.2+/-7.0 uM in human brain synaptosomes and human liver mitochondria respectively.
In Vivo: Bifemelane (20-80 mg/kg; i.p.) dose-dependently decreases exploratory activity in the open field test.

Bifemelane (20-80 mg/kg; i.p.) decreases immobility time in the forced swim test, although is not clearly dosedependent and has already reached ceiling at 20 mg/kg.